期刊文献+

STAT3在血管平滑肌细胞中的作用及其机制的最新进展 被引量:2

下载PDF
导出
摘要 STAT(signal transducer and activator of transcription)3是酪氨酸激酶(Januskinase,JAK)/STAT信号转导通路中重要的信号转录因子,人类STAT家族包括7类蛋白,分别为STATl~4、STAT5A、STAT5B和STAT6,
出处 《上海医学》 CAS CSCD 北大核心 2014年第7期621-627,共7页 Shanghai Medical Journal
  • 相关文献

参考文献1

二级参考文献162

  • 1Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Statl activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 1998, 102:1385 - 1392.
  • 2Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcino-genesis in vivo. Proc Natl Acad Sci USA 2000, 97:4227-4232.
  • 3Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998,394:145- 151.
  • 4Gray M J, Zhang J, Ellis LM, et al. HIF- 1 alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005, 24:3110- 3120.
  • 5Loeffler S, Fayard B, Weis J, Weissenberger J. Intedeukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Spl. IntJ Cancer 2005,115:202-213.
  • 6Albanell J, Rojo F, Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol 2001, 28:56-66.
  • 7Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD 1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005,113:109-115.
  • 8Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Group ECO. Phase III randomized trial ofcisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005, 23:8646-8654.
  • 9Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 2005, 5:1085-1093.
  • 10Vincent PW, Bridges A J, Dykes D J, et al. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts. Cancer ChemotherPharmacol 2000, 45:231-238.

共引文献71

同被引文献53

  • 1王全伟,凡文博,王智昊,吴扬.氧化应激与心血管疾病关系的研究进展[J].中国老年学杂志,2014,34(1):270-273. 被引量:60
  • 2郑建普,卞卡,可燕,Murad Ferid.内皮型一氧化氮合酶脱偶联的研究进展[J].中国药理学通报,2006,22(6):659-663. 被引量:29
  • 3ChobanianAV,BakrisGL,BlackHR,etal.SeventhreportoftheJointNationalCommitteeonPrevention,Detection,Evaluation,andTreatmentofHighBloodPressure[J].Hypertension,2003,42:1206-1252.
  • 4HwangJW,YaoH,CaitoS,etal.RedoxregulationofSIRT1ininflammationandcellularsenescence[J].FreeRadicBiolMed,2013,61:95-110.
  • 5BrionesAM,TouyzRM.Oxidativestressandhypertension:currentconcepts[J].CurrHypertensRep,2010,12(2):135-142.
  • 6StanicB,KatsuyamaM,MillerFJJr.Anoxidizedextracellularoxidation-reductionstateincreasesNox1expressionandproliferationinvascularsmoothmusclecellsviaepidermalgrowthfactorreceptoractivation[J].ArteriosclerThrombVascBiol,2010,30(11):2234-2241.
  • 7CaiH,GriendlingKK,HarrisonDG.ThevascularNAD(P)H oxidasesastherapeutictargetsincardiovasculardiseases[J].TrendsPharmacolSci,2003,24(9):471-478.
  • 8SorescuD,GriendlingKK.Reactiveoxygenspecies,mitochondria,andNAD(P)H oxidasesinthedevelopmentandprogressionofheartfailure[J].CongHeartFail,2002,8(3):132-140.
  • 9ParaviciniTM,TouyzRM.Redoxsignalinginhypertension[J].CardiovascRes,2006,71(2):247-258.
  • 10LiH,HorkeS,FrstermannU.Oxidativestressinvasculardiseaseanditspharmacologicalprevention[J].TrendsPharmacolSci,2013,34(6):313-319.

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部